Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
No clinical interaction between sitaxsentan and sildenafil Source: Eur Respir J 2005; 26: Suppl. 49, 563s Year: 2005
No relevant drug-drug interaction between inhaled NVA237 and oral cimetidine Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
‘Total PDE4 inhibitory activity‘: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N-oxide in special populations and drug-drug interactions Source: Eur Respir J 2006; 28: Suppl. 50, 436s Year: 2006
The effects of multiple dosing of ketoconazole on the pharmacokinetics of a single dose ambrisentan Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone Source: Eur Respir J, 53 (1) 1801060; 10.1183/13993003.01060-2018 Year: 2019
Roflumilast and sildenafil in healthy male volunteers: Single-dose pharmacokinetic interactions, safety and tolerability Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Effects of steady-state female hormones on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Effects of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide Source: Annual Congress 2009 - New bronchodilators Year: 2009
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012
Late Breaking Abstract - Pharmacokinetic and pharmacodynamic interactions between components of extrafine formulation of BDP/FF/GB, a novel fixed-dose triple combination for asthma and COPD Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Safety and pharmacokinetics of nintedanib plus sildenafil in the INSTAGE trial Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019
Epoprostenol with expanded stability has the same pharmacokinetic and hemodynamic profiles as epoprostenol in healthy subjects Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Safety and efficacy of bosentan in combination with sildenafil in pulmonary arterial hypertension: The COMPASS-3 study Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011
Pharmacodynamic effects of nebulised bronchodilator combinations Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Effect of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension Source: Eur Respir J, 56 (3) 2000673; 10.1183/13993003.00673-2020 Year: 2020
The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing Source: Annual Congress 2011 - Understanding disease and drug mechanisms Year: 2011
Pharmacodynamic and pharmacokinetic results after repeated doses of AZD8871 in COPD patients Source: International Congress 2018 – Clinical trials in COPD: new results Year: 2018